Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Growth Disorder Clear all
Recruiting No phase listed Observational

The Fibrodysplasia Ossificans Progressiva (FOP) Registry

NCT02745158
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
Not listed
Lead sponsor
The International FOP Association
Other
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2040
U.S. locations
1
States / cities
North Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jun 10, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

NCT02049957
View directory record Official record
Conditions
Breast Cancer
Interventions
Sapanisertib, Fulvestrant, Exemestane
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
30
States / cities
Los Angeles, California • San Francisco, California • Santa Barbara, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jun 10, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.

NCT02571972
View directory record Official record
Conditions
Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
Dorzolamide-timolol
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Jun 10, 2026, 2:23 PM EDT
Completed Phase 2 Interventional

Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer

NCT00063401
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Neoplasms
Interventions
Cetuximab:, Paclitaxel, Carboplatin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2010 · Synced Jun 10, 2026, 2:23 PM EDT
Recruiting No phase listed Observational

Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation

NCT05952583
View directory record Official record
Conditions
Twin; Pregnancy, Affecting Fetus or Newborn, Fetal Growth Retardation, Twin Monochorionic Diamniotic Placenta, Twin Diseases
Interventions
Ultrasound
Diagnostic Test
Lead sponsor
Leiden University Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2024 · Synced Jun 10, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer

NCT03454529
View directory record Official record
Conditions
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
Interventions
Laboratory Biomarker Analysis, Simvastatin
Other · Drug
Lead sponsor
Michael Simon
Other
Eligibility
19 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Jun 10, 2026, 2:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nociceptive Pain Fiber Response

NCT02696070
View directory record Official record
Conditions
Painful Peripheral Diabetic Neuropathy
Interventions
Provant Therapy System
Device
Lead sponsor
Regenesis Biomedical, Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Jun 10, 2026, 2:23 PM EDT
Completed Phase 1Phase 2 Interventional

Versartis Trial in Children to Assess Long-Acting Growth Hormone

NCT01718041
View directory record Official record
Conditions
Pediatric Growth Hormone Deficiency
Interventions
Experimental: VRS-317
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
3 Years to 11 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
23
States / cities
Clovis, California • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Jun 10, 2026, 2:23 PM EDT
Completed Not applicable Interventional

Evaluate Initial Safety of the HemiBridge™ System in Guided Spinal Growth Treatment of Progressive Idiopathic Scoliosis

NCT01465295
View directory record Official record
Conditions
Scoliosis
Interventions
Mechanical hemiepiphysiodesis using the HemiBridge System
Device
Lead sponsor
SpineForm LLC
Industry
Eligibility
10 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Cincinnati, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2018 · Synced Jun 10, 2026, 2:23 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Growth Hormone and Chromosome 18q- and Abnormal Growth

NCT00134420
View directory record Official record
Conditions
Loss of Chromosome 18q, Growth Hormone Deficiency
Interventions
Nutropin AQ, Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, Neuropsychological Testing
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Up to 18 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2016 · Synced Jun 10, 2026, 2:23 PM EDT
Completed Phase 2Phase 3 Interventional

Probiotics-Supplemented Feeding in Extremely Low Birth Weight Infants

NCT01164124
View directory record Official record
Conditions
Low Birth Weight
Interventions
Probiotic supplementation (Lactobacillus rhamnosus GG and Bifidobacterium infantis), Placebo
Dietary Supplement · Other
Lead sponsor
Vermont Oxford Network
Network
Eligibility
1 Day to 14 Days
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Detroit, Michigan • St Louis, Missouri • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Jun 10, 2026, 2:23 PM EDT
Active, not recruiting No phase listed Observational

Post-Discharge Growth of Infants Who Received Donor Human Milk Products in the Neonatal Intensive Care Unit (NICU)

NCT01483079
View directory record Official record
Conditions
Prematurity
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jun 10, 2026, 2:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

NCT05735080
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer
Interventions
INX-315, Fulvestrant, Abemaciclib
Drug
Lead sponsor
Incyclix Bio
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
15
States / cities
Orlando, Florida • Atlanta, Georgia • Augusta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jun 10, 2026, 2:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Healthy Sleeping and Feeding During Infancy

NCT00125580
View directory record Official record
Conditions
Obesity
Interventions
Infant sleep instruction
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
2
States / cities
Hershey, Pennsylvania • University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Jun 10, 2026, 2:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Self Regulated Physical Activity and Bone Growth Enhancement in Premature Infants

NCT03884322
View directory record Official record
Conditions
Prematurity, VLBW - Very Low Birth Weight Infant
Interventions
Prepod, Joint compression exercises
Other · Procedure
Lead sponsor
Asante Health System
Other
Eligibility
32 Weeks to 36 Weeks
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Jun 10, 2026, 2:23 PM EDT
Active, not recruiting Phase 3 Interventional

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

NCT05973773
View directory record Official record
Conditions
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Interventions
TAS6417
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Henderson, Nevada • Las Vegas, Nevada • Canton, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jun 10, 2026, 2:23 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)

NCT02835794
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Omacetaxine, Azacitidine, G-CSF
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Jun 10, 2026, 2:23 PM EDT
Completed Phase 4 Interventional Results available

A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency

NCT02311894
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Somatropin
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
3 Years to 14 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
33
States / cities
Little Rock, Arkansas • Orange, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Jun 10, 2026, 2:23 PM EDT
Recruiting Not applicable Interventional

Impact of Early Fortini Initiation on Growth and Interstage Outcomes in Infants With Single Ventricle Physiology

NCT07087782
View directory record Official record
Conditions
Single-ventricle
Interventions
Fortini formula, Standard Nutritional Care
Other
Lead sponsor
Driscoll Children's Hospital
Other
Eligibility
0 Months to 6 Months
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Corpus Christi, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 10, 2026, 2:23 PM EDT
Terminated Not applicable Interventional Results available

Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer

NCT00503841
View directory record Official record
Conditions
Breast Cancer
Interventions
erlotinib hydrochloride, immunohistochemistry staining method, laboratory biomarker analysis, biopsy, conventional surgery, neoadjuvant therapy
Drug · Other · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Jun 10, 2026, 2:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Type 1 Diabetes and the Brain in Children

NCT02351466
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Observational
Other
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
7 Years to 16 Years
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
5
States / cities
Palo Alto, California • New Haven, Connecticut • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Jun 10, 2026, 2:23 PM EDT
Withdrawn Not applicable Interventional

Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - CHMCO

NCT03673566
View directory record Official record
Conditions
Preterm Birth, Low; Birthweight, Extremely (999 Grams or Less), Neonatal Infection, Satisfaction, Stress, Chronic Lung Disease, Growth Acceleration, Adverse Event
Interventions
NICU Dashboard
Device
Lead sponsor
Philips Healthcare
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Jun 10, 2026, 2:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lifestyle Intervention in Preparation for Pregnancy (LIPP)

NCT03146156
View directory record Official record
Conditions
Obesity, Lifestyle-related Condition, Macrosomia, Fetal
Interventions
Lifestyle Intervention
Behavioral
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
4
States / cities
Baton Rouge, Louisiana • Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Jun 10, 2026, 2:23 PM EDT
Completed No phase listed Observational Results available

Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease

NCT00062166
View directory record Official record
Conditions
Von Hippel-Lindau Disease
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 80 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Jun 10, 2026, 2:23 PM EDT